

Jacques Simard

List of Publications by Citations

Source: <https://exaly.com/author-pdf/912325/jacques-simard-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

345
papers

21,029
citations

70
h-index

133
g-index

362
ext. papers

24,857
ext. citations

8.1
avg, IF

5.54
L-index

#	Paper	IF	Citations
345	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2402-2416	27.4	1140
344	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013 , 45, 353-61, 361e1-2	36.3	813
343	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017 , 551, 92-94	50.4	643
342	A candidate prostate cancer susceptibility gene at chromosome 17p. <i>Nature Genetics</i> , 2001 , 27, 172-80	36.3	469
341	Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. <i>Endocrine Reviews</i> , 2003 , 24, 152-82	27.2	445
340	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
339	The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. <i>Steroids</i> , 1997 , 62, 148-58	2.8	418
338	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 134-47	4	411
337	Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. <i>Endocrine Reviews</i> , 2005 , 26, 525-82	27.2	408
336	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015 , 47, 373-80	36.3	406
335	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013 , 45, 392-8, 398e1-2	36.3	327
334	Prediction of breast cancer risk based on profiling with common genetic variants. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	324
333	Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. <i>Molecular Endocrinology</i> , 1991 , 5, 1147-57		313
332	DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. <i>Steroids</i> , 1998 , 63, 322-8	2.8	301
331	BRCA2 germline mutations in male breast cancer cases and breast cancer families. <i>Nature Genetics</i> , 1996 , 13, 123-5	36.3	289
330	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286
329	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276

328	DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. <i>Frontiers in Neuroendocrinology</i> , 2001 , 22, 185-212	8.9	267
327	Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5' termini in human placenta. <i>Molecular Endocrinology</i> , 1989 , 3, 1301-9		262
326	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015 , 47, 1294-1303	36.3	226
325	The emergence of an ethical duty to disclose genetic research results: international perspectives. <i>European Journal of Human Genetics</i> , 2006 , 14, 1170-8	5.3	221
324	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>American Journal of Human Genetics</i> , 2008 , 82, 937-48	11	218
323	DHEA and peripheral androgen and estrogen formation: intracrinology. <i>Annals of the New York Academy of Sciences</i> , 1995 , 774, 16-28	6.5	218
322	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
321	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. <i>American Journal of Human Genetics</i> , 2007 , 81, 1186-200	11	204
320	Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. <i>Nature Genetics</i> , 1992 , 1, 239-45	36.3	199
319	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. <i>Genetics in Medicine</i> , 2019 , 21, 1708-1718	8.1	192
318	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
317	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
316	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 126-135	4	183
315	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
314	Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. <i>Molecular Endocrinology</i> , 1990 , 4, 268-75		171
313	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. <i>American Journal of Human Genetics</i> , 2013 , 92, 489-503	11	167
312	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	153
311	Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS CollaboratorsMGroup. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3361-6	2.2	150

310	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1999 , 69, 51-84	5.1	149
309	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. <i>Cancer Research</i> , 2010 , 70, 9742-54	10.1	147
308	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
307	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018 , 39, 593-620	4.7	138
306	(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyloxy)phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 2117-22	8.3	131
305	A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. <i>American Journal of Human Genetics</i> , 2005 , 77, 219-29	11	129
304	Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. <i>Endocrine Reviews</i> , 2005 , 26, 361-79	27.2	125
303	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121
302	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3091-9	2.2	118
301	Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. <i>American Journal of Human Genetics</i> , 1998 , 62, 653-8	11	112
300	Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 601-10	4	110
299	Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. <i>Trends in Endocrinology and Metabolism</i> , 2000 , 11, 421-7	8.8	109
298	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
297	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2240-2250	2.2	101
296	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978	36.3	101
295	Regulation of progesterone-binding breast cyst protein GCDPF-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. <i>Endocrinology</i> , 1990 , 126, 3223-31	4.8	96
294	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016 , 48, 374-86	36.3	93
293	Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. <i>Endocrinology</i> , 1989 , 125, 392-9	4.8	93

292	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009 , 18, 4442-56	5.6	91
291	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003173	6	90
290	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014 , 4, 4999	17.4	87
289	Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats. <i>Molecular Endocrinology</i> , 1989 , 3, 1748-56		86
288	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	85
287	Structure and sexual dimorphic expression of a liver-specific rat 3 beta-hydroxysteroid dehydrogenase/isomerase. <i>Endocrinology</i> , 1990 , 127, 3237-9	4.8	83
286	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013 , 93, 1046-60	11	80
285	Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture. <i>Endocrinology</i> , 1986 , 119, 2004-11	4.8	80
284	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016 , 13, e1002105	11.6	80
283	Genetic discrimination and life insurance: a systematic review of the evidence. <i>BMC Medicine</i> , 2013 , 11, 25	11.4	78
282	GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. <i>Molecular Endocrinology</i> , 2005 , 19, 2358-70		78
281	New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 84, 1118-25	5.6	77
280	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76
279	Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. <i>Endocrinology</i> , 1989 , 124, 2745-54	4.8	75
278	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	74
277	Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 1007-12	9.4	71
276	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012 , 14, R33	8.3	70
275	Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. <i>Cancer</i> , 1993 , 71, 1059-67	6.4	67

274	Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995 , 53, 127-38	5.1	66
273	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	65
272	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 687-705	19.4	64
271	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64
270	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. <i>Breast Cancer Research</i> , 2006 , 8, R3	8.3	64
269	Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase. <i>FEBS Letters</i> , 1989 , 259, 153-7	3.8	64
268	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. <i>Genetics in Medicine</i> , 2016 , 18, 1190-1198	8.1	64
267	Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. <i>Molecular Endocrinology</i> , 1999 , 13, 66-81		63
266	Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization. <i>Endocrinology</i> , 1990 , 127, 1394-403	4.8	63
265	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
264	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 3304-21	5.6	62
263	Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency. <i>Steroids</i> , 1997 , 62, 176-84	2.8	61
262	The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. <i>DNA and Cell Biology</i> , 1995 , 14, 849-61	3.6	61
261	Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. <i>Human Molecular Genetics</i> , 1993 , 2, 1193-9	5.6	61
260	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015 , 96, 5-20	11	59
259	Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate. <i>Molecular and Cellular Endocrinology</i> , 1991 , 75, 101-10	4.4	59
258	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2007 , 44, 107-21	5.8	58
257	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56

256	The Tumor Suppressor PALB2: Inside Out. <i>Trends in Biochemical Sciences</i> , 2019 , 44, 226-240	10.3	56
255	Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. <i>Human Genetics</i> , 2006 , 120, 471-85	6.3	55
254	Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. <i>Baillieres Clinical Endocrinology and Metabolism</i> , 1994 , 8, 451-74		55
253	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015 , 24, 5589-602	5.6	54
252	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
251	Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. <i>International Journal of Cancer</i> , 1997 , 73, 104-12	7.5	53
250	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019 , 48, 795-806	7.8	52
249	Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. <i>Seminars in Reproductive Medicine</i> , 2002 , 20, 255-76	1.4	51
248	Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. <i>Endocrinology</i> , 1999 , 140, 4573-84	4.8	51
247	Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. <i>Molecular Endocrinology</i> , 1989 , 3, 694-702		50
246	Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin. <i>Endocrinology</i> , 1990 , 127, 2726-37	4.8	50
245	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 6096-111	5.6	48
244	Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1996 , 121, 11-8	4.4	48
243	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019 , 10, 1741	17.4	47
242	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014 , 16, 3416	8.3	46
241	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
240	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015 , 75, 2457-67	10.1	45
239	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 645-57	4	44

238	Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? <i>Cancer Research</i> , 2004 , 64, 840-3	10.1	44
237	Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. <i>Human Genetics</i> , 2005 , 117, 119-32	6.3	44
236	No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. <i>Genetic Testing and Molecular Biomarkers</i> , 2006 , 10, 104-15		43
235	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016 , 99, 903-911	11	43
234	No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 2862-7	4	41
233	Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis. <i>Endocrinology</i> , 1990 , 127, 1986-94	4.8	41
232	EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 79, 213-25	5.1	40
231	Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21. <i>Genomics</i> , 1995 , 28, 530-42	4.3	39
230	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. <i>PLoS Genetics</i> , 2014 , 10, e1004285	6	38
229	Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. <i>BMC Cancer</i> , 2006 , 6, 230	4.8	38
228	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. <i>Molecular and Cellular Endocrinology</i> , 2001 , 171, 25-40	4.4	38
227	Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. <i>Neuroendocrinology</i> , 1990 , 52, 527-36	5.6	38
226	MicroRNA related polymorphisms and breast cancer risk. <i>PLoS ONE</i> , 2014 , 9, e109973	3.7	37
225	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 105-16	9.7	37
224	Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. <i>Genetic Testing and Molecular Biomarkers</i> , 2007 , 11, 45-54		37
223	Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. <i>Prostate</i> , 2003 , 57, 270-9	4.2	37
222	Perspective: prostate cancer susceptibility genes. <i>Endocrinology</i> , 2002 , 143, 2029-40	4.8	37
221	Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1994 , 51, 167-74	5.1	37

220	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015 , 24, 2966-84	5.6	36
219	Potent stimulatory effect of interleukin-1 alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells. <i>International Journal of Cancer</i> , 1994 , 59, 400-7	7.5	36
218	Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. <i>International Journal of Cancer</i> , 1995 , 62, 732-7	7.5	36
217	Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland. <i>Endocrinology</i> , 1989 , 125, 1821-8	4.8	36
216	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015 , 24, 285-98	5.6	35
215	Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. <i>Urology</i> , 1997 , 49, 580-6; discussion 586-9	1.6	35
214	Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat. <i>Molecular and Cellular Endocrinology</i> , 1994 , 99, 63-71	4.4	35
213	Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. <i>Genomics</i> , 1996 , 36, 86-99	4.3	34
212	Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs. <i>Molecular and Cellular Endocrinology</i> , 1988 , 55, 233-42	4.4	34
211	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020 , 22, 1653-1666	8.1	34
210	Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry. <i>Breast Cancer Research</i> , 2016 , 18, 124	8.3	34
209	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
208	Personalized medicine and access to health care: potential for inequitable access?. <i>European Journal of Human Genetics</i> , 2013 , 21, 143-7	5.3	33
207	Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCI in high-risk non-BRCA1/BRCA2 breast cancer families. <i>Journal of Human Genetics</i> , 2008 , 53, 579	4.3	33
206	Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007 , 29, 45-60	1.3	33
205	Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. <i>Journal of Investigative Dermatology</i> , 1995 , 105, 678-82	4.3	33
204	Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. <i>Human Molecular Genetics</i> , 1994 , 3, 1639-45	5.6	33
203	Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. <i>Human Molecular Genetics</i> , 1994 , 3, 1685-91	5.6	33

202	Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin. <i>Human Molecular Genetics</i> , 1994 , 3, 327-30	5.6	33
201	Synthesis and antiestrogenic activity of diaryl thioether derivatives. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 1115-25	8.3	33
200	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. <i>Nature Communications</i> , 2020 , 11, 3353	17.4	32
199	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
198	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2859-68 ⁴		32
197	Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. <i>Molecular Endocrinology</i> , 2002 , 16, 1696-710		32
196	Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. <i>Human Molecular Genetics</i> , 1993 , 2, 479-83	5.6	32
195	Life insurance: genomic stratification and risk classification. <i>European Journal of Human Genetics</i> , 2014 , 22, 575-9	5.3	31
194	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012 , 33, 690-702	4.7	31
193	Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. <i>Journal of Genetic Counseling</i> , 2008 , 17, 314-26	2.5	31
192	Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. <i>Biochemistry</i> , 1995 , 34, 2893-900	3.2	31
191	Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. <i>Neuroscience Letters</i> , 1991 , 127, 96-8	3.3	31
190	Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. <i>DNA and Cell Biology</i> , 1986 , 5, 263-70		31
189	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. <i>Nature Communications</i> , 2020 , 11, 3833	17.4	31
188	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016 , 18, 22	8.3	31
187	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. <i>Breast Cancer Research</i> , 2013 , 15, 402	8.3	30
186	A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1968-74	5.6	30
185	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019 , 120, 647-657	8.7	28

184	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 1934-46	5.6	28
183	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998 , 65, 151-62	5.1	28
182	Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. <i>Molecular and Cellular Endocrinology</i> , 1990 , 68, 169-79	4.4	28
181	Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. <i>Molecular and Cellular Endocrinology</i> , 1985 , 39, 141-4	4.4	28
180	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015 , 97, 22-34	11	26
179	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , 2015 , 10, e0120020	3.7	26
178	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1416-21	4	26
177	Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002 , 82, 55-63	5.1	26
176	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016 , 139, 1303-1317	7.5	26
175	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>JAMA Oncology</i> , 2020 , 6, 1218-1230	13.4	25
174	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016 , 18, 112	8.3	25
173	Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995 , 55, 489-505	5.1	25
172	Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland. <i>Molecular Endocrinology</i> , 1988 , 2, 775-84		25
171	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016 , 18, 64	8.3	25
170	Inherited mutations in and in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. <i>Journal of Medical Genetics</i> , 2018 , 55, 97-103	5.8	24
169	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. <i>Human Molecular Genetics</i> , 2016 , 25, 3863-3876	5.6	24
168	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. <i>Genetic Epidemiology</i> , 2014 , 38, 84-93	2.6	24
167	Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. <i>Human Mutation</i> , 1998 , Suppl 1, S226-31	4.7	24

166	The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 76-9	4	24
165	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. <i>Journal of Lipid Research</i> , 2003 , 44, 1508-14	6.3	24
164	Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. <i>Human Genetics</i> , 1995 , 95, 545-50	6.3	24
163	Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. <i>Genomics</i> , 1995 , 25, 724-6	4.3	24
162	Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians. <i>Human Mutation</i> , 1995 , 6, 243-6	4.7	24
161	Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization. <i>Endocrinology</i> , 1991 , 129, 2687-92	4.8	24
160	Return of research results: general principles and international perspectives. <i>Journal of Law, Medicine and Ethics</i> , 2011 , 39, 583-92	1.2	23
159	Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2010 , 14, 515-26	1.6	23
158	Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003 , 87, 167-79	5.1	23
157	Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture. <i>Molecular Endocrinology</i> , 1988 , 2, 521-7		23
156	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020 , 22, 8	8.3	22
155	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
154	Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase. <i>Annals of the New York Academy of Sciences</i> , 1990 , 595, 40-52	6.5	22
153	Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells. <i>Annals of the New York Academy of Sciences</i> , 1990 , 595, 130-48	6.5	22
152	A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. <i>Nucleic Acids Research</i> , 2019 , 47, 10662-10677	20.1	22
151	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 350-364	9.7	22
150	Family communication following BRCA1/2 genetic testing: a close look at the process. <i>Journal of Genetic Counseling</i> , 2013 , 22, 323-35	2.5	21
149	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 4732-47	5.6	21

148	Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. <i>Molecular Endocrinology</i> , 2000 , 14, 229-40		21
147	Parallel solid-phase synthesis of a model library of 7alpha-alkylamide estradiol derivatives as potential estrogen receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999 , 9, 2827-32	2.9	21
146	Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion. <i>Regulatory Peptides</i> , 1986 , 15, 269-78		21
145	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016 , 7, 80140-80163	3.3	21
144	Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. <i>Nature Communications</i> , 2019 , 10, 5296	17.4	21
143	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 308-16	4	20
142	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020 , 11, 312	17.4	20
141	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1362-70	4	20
140	Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 76, 213-25	5.1	20
139	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. <i>Atherosclerosis</i> , 1999 , 143, 145-51	3.1	20
138	Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17. <i>The Journal of Steroid Biochemistry</i> , 1989 , 34, 189-97		20
137	Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release. <i>Peptides</i> , 1987 , 8, 199-205	3.8	20
136	Functional characterization of 84 PALB2 variants of uncertain significance. <i>Genetics in Medicine</i> , 2020 , 22, 622-632	8.1	20
135	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015 , 6, 37979-94	3.3	19
134	Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7. <i>Genomics</i> , 1992 , 14, 63-9	4.3	19
133	Multiple factors controlling ACTH secretion at the anterior pituitary level. <i>Annals of the New York Academy of Sciences</i> , 1987 , 512, 97-114	6.5	19
132	Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. <i>The Journal of Steroid Biochemistry</i> , 1987 , 26, 539-46		19
131	The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. <i>Human Molecular Genetics</i> , 1994 , 3, 1679-82	5.6	18

130	Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. <i>The Journal of Steroid Biochemistry</i> , 1989 , 34, 397-402		18
129	Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. <i>Regulatory Peptides</i> , 1991 , 33, 263-73		18
128	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0153788	3.7	18
127	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019 , 144, 1195-1204	7.5	18
126	Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 295-304	9.7	18
125	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1680-91	4	17
124	Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 397-402	4	17
123	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. <i>International Journal of Epidemiology</i> , 2020 , 49, 1117-1131	7.8	17
122	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. <i>Nature Communications</i> , 2020 , 11, 1217	17.4	16
121	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). <i>Scientific Reports</i> , 2016 , 6, 32512	4.9	16
120	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 61	8.3	16
119	A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency. <i>Endocrine Research</i> , 2000 , 26, 761-70	1.9	16
118	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15
117	Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1997 , 1350, 98-108		15
116	Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2005 , 20, 165-77	5.6	15
115	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016 , 27, 679-93	2.8	15
114	A focus group study on breast cancer risk presentation: one format does not fit all. <i>European Journal of Human Genetics</i> , 2013 , 21, 719-24	5.3	14
113	Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. <i>European Journal of Human Genetics</i> , 2011 , 19, 494-9	5.3	14

112	Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 49-53		14
111	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019 , 121, 180-192	8.7	13
110	Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. <i>European Journal of Human Genetics</i> , 2013 , 21, 903-10	5.3	13
109	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017 , 141, 1830-1840	7.5	13
108	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. <i>Frontiers in Genetics</i> , 2017 , 8, 128	4.5	13
107	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. <i>Advances in Protein Chemistry</i> , 2001 , 56, 293-368		13
106	Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDPF-15 expression in ZR-75-1 human breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1990 , 73, 171-8	4.4	13
105	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	13
104	A response to "Personalised medicine and population health: breast and ovarian cancer". <i>Human Genetics</i> , 2019 , 138, 287-289	6.3	13
103	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky023	4.6	13
102	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. <i>Cancer Research</i> , 2018 , 78, 6329-6338	10.1	13
101	Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease. <i>Public Health Reviews</i> , 2019 , 40, 2	4.3	12
100	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015 , 36, 256-71	4.6	12
99	The p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 38	7.8	12
98	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014 , 16, R51	8.3	12
97	Life events may contribute to family communication about cancer risk following BRCA1/2 testing. <i>Journal of Genetic Counseling</i> , 2013 , 22, 249-57	2.5	12
96	Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. <i>Nutrition and Cancer</i> , 2006 , 54, 157-65	2.8	12
95	Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13). <i>Human Genetics</i> , 1991 , 87, 753-4	6.3	12

94	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. <i>European Journal of Epidemiology</i> , 2019 , 34, 591-600	12.1	11
93	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014 , 23, 6034-46	5.6	11
92	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 185-92	4.4	11
91	Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009 , 116, 134-53	5.1	11
90	Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. <i>Journal of Molecular Endocrinology</i> , 2008 , 40, 161-72	4.5	11
89	CYP17 and breast cancer: no overall effect, but what about interactions?. <i>Breast Cancer Research</i> , 2005 , 7, 238-42	8.3	11
88	Partnering in oncogenetic research--the INHERIT BRCA's experience: opportunities and challenges. <i>Familial Cancer</i> , 2006 , 5, 3-13	3	11
87	A new alternative splice variant of BRCA1 containing an additional in-frame exon. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005 , 1731, 57-65		11
86	Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region. <i>Genomics</i> , 1995 , 29, 781-3	4.3	11
85	Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture. <i>Molecular and Cellular Endocrinology</i> , 1986 , 46, 79-89	4.4	11
84	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016 , 11, e0160316	3.7	11
83	Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings. <i>Public Health Genomics</i> , 2014 , 17, 190-208	1.9	10
82	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. <i>Journal of Human Genetics</i> , 2007 , 52, 963-977	4.3	10
81	Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2004 , 1679, 230-47		10
80	Assignment of the gene encoding the catalytic subunit C beta of cAMP-dependent protein kinase to the p36 band on chromosome 1. <i>Human Genetics</i> , 1992 , 88, 653-7	6.3	10
79	Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 434-442	9.7	10
78	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky078	4.6	10
77	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. <i>EBioMedicine</i> , 2019 , 48, 203-211	8.8	9

76	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020 , 44, 442-468	2.6	9
75	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 368-378	4	9
74	Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 974-8	3.5	9
73	17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2005 , 18, 403-11	1.6	9
72	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. <i>International Journal of Cancer</i> , 2020 , 146, 2130-2138	7.5	9
71	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 51.e1-51.e17	6.4	9
70	Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. <i>Familial Cancer</i> , 2012 , 11, 27-32	3	8
69	Localization of BRCA1 gene expression in adult cynomolgus monkey tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 1997 , 45, 1173-88	3.4	8
68	Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2004 , 26, 1059-66	1.3	8
67	Localization and regulation of expression of the FAR-17A gene in the hamster flank organs. <i>Journal of Investigative Dermatology</i> , 1996 , 107, 44-50	4.3	8
66	Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin. <i>Journal of Investigative Dermatology</i> , 1994 , 103, 60-4	4.3	8
65	Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family. <i>Molecular and Cellular Endocrinology</i> , 1994 , 103, 29-38	4.4	8
64	The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. <i>Familial Cancer</i> , 2016 , 15, 1-17	3	7
63	Systematic mixed-methods reviews are not ready to be assessed with the available tools. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 926-8	5.7	7
62	Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study. <i>Genetics in Medicine</i> , 2012 , 14, 60-8	8.1	7
61	Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer. <i>Journal of Human Genetics</i> , 2008 , 53, 490-498	4.3	7
60	Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells. <i>Annals of the New York Academy of Sciences</i> , 1990 , 586, 174-87	6.5	7
59	Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives. <i>Healthcare Policy</i> , 2019 , 15, 39-54	1.1	7

58	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016 , 11, e0158801	3.7	7
57	Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control. <i>Genes</i> , 2019 , 10,	4.2	6
56	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2016 , 135, 137-54	6.3	6
55	Functional analysis of promoter variants in KU70 and their role in cancer susceptibility. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 1007-13	5	6
54	Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008 , 109, 115-28	5.1	6
53	Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience. <i>Cancer and Metastasis Reviews</i> , 1987 , 6, 615-36	9.6	6
52	Transcriptional signature of lymphoblastoid cell lines of , and non- high risk breast cancer families. <i>Oncotarget</i> , 2017 , 8, 78691-78712	3.3	6
51	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. <i>International Journal of Epidemiology</i> , 2021 ,	7.8	6
50	Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening. <i>New Genetics and Society</i> , 2019 , 38, 38-59	1.9	6
49	Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada). <i>BMJ Open</i> , 2018 , 8, e016662	3	5
48	Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?. <i>American Journal of Preventive Medicine</i> , 2017 , 53, e195-e196	6.1	5
47	SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation. <i>Genetic Epidemiology</i> , 2015 , 39, 406-14	2.6	5
46	Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility. <i>Psycho-Oncology</i> , 2012 , 21, 515-23	3.9	5
45	Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 281-5	4.4	5
44	Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 157-60	4	5
43	Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 425-427	4	4
42	Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?. <i>Familial Cancer</i> , 2017 , 16, 35-40	3	4
41	Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. <i>Genetics in Medicine</i> , 2016 , 18, 627-34	8.1	4

40	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
39	Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	4
38	DSNetwork: An Integrative Approach to Visualize Predictions of Variants' Deleteriousness. <i>Frontiers in Genetics</i> , 2019 , 10, 1349	4.5	3
37	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 295-302	4.4	3
36	The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 521-7	4.4	3
35	Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility. <i>Psychological Reports</i> , 2006 , 98, 873-81	1.6	3
34	Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 97, 289-98	5.1	3
33	Genomic organization and expression of the mouse Brca2 gene. <i>Mammalian Genome</i> , 2002 , 13, 352-8	3.2	3
32	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
31	- a novel candidate breast cancer susceptibility locus on 6q14.1. <i>Oncotarget</i> , 2017 , 8, 102769-102782	3.3	3
30	Association of germline variation with the survival of women with pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 44	7.8	3
29	ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. <i>PLoS ONE</i> , 2016 , 11, e0156820	3.7	3
28	Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers. <i>Canadian Association of Radiologists Journal</i> , 2016 , 67, 308-312	3.9	3
27	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. <i>Genetics in Medicine</i> , 2021 , 23, 2114-2121	8.1	3
26	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
25	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
24	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019 , 9, 12524	4.9	2
23	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020 , 10, 9688	4.9	2

22	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016 , 6, 36874	4.9	2
21	VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis. <i>Bioinformatics</i> , 2017 , 33, 1389-1391	7.2	2
20	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. <i>Npj Breast Cancer</i> , 2021 , 7, 52	7.8	2
19	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021 , 2, 100042-100042	8.8	2
18	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021 , 23, 1726-1737	8.1	2
17	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021 , 124, 842-854	8.7	2
16	Polygenic risk scores for prediction of breast cancer risk in Asian populations.. <i>Genetics in Medicine</i> , 2021 ,	8.1	2
15	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGR genetic variants and breast cancer risk. <i>International Journal of Epidemiology</i> , 2019 , 48, 1727-1730	7.8	1
14	Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. <i>Biostatistics</i> , 2020 , 21, 518-530	3.7	1
13	HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2005 , 27, 321; author reply 322	1.3	1
12	Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences		1
11	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
10	A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study. <i>Cancers</i> , 2021 , 13,	6.6	1
9	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
8	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021 , 108, 1190-1203	11	1
7	PALB2 Variants: Protein Domains and Cancer Susceptibility. <i>Trends in Cancer</i> , 2021 , 7, 188-197	12.5	1
6	Rare germline copy number variants (CNVs) and breast cancer risk.. <i>Communications Biology</i> , 2022 , 5, 65	6.7	0
5	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021 , 125, 1135-1145	8.7	0

4	Women's perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform.. <i>Hereditary Cancer in Clinical Practice</i> , 2022 , 20, 8	2.3	○
3	A Genome-Wide Gene-Based Gene-Environment Interaction Study of Breast Cancer in More than 90,000 Women. <i>Cancer Research Communications</i> , 2022 , 2, 211-219		○
2	Authors' response: Associations of obesity and circulating insulin and glucose with breast cancer risk. <i>International Journal of Epidemiology</i> , 2019 , 48, 1016-1017	7.8	
1	BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey. <i>Annals of the New York Academy of Sciences</i> , 1998 , 839, 444-6	6.5	